A Phase I/II study of crizotinib for recurrent or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma and a phase i study of crizotinib for recurrent or refractory neuroblastoma: Study protocol for a multicenter single-arm open-label trial

Masahiro Sekimizu, Tomoo Osumi, Reiji Fukano, Yuhki Koga, Akiko Kada, Akiko M. Saito, Tetsuya Mori

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Crizotinib is an inhibitor of multiple tyrosine kinases, including the anaplastic lymphoma kinase (ALK). Responses to crizotinib have also been reported in patients with ALK-positive anaplastic large-cell lymphoma (ALCL) and solid tumors with ALK-mutation, including neuroblastoma. Optimal treatment for patients with recurrent or refractory ALK-positive ALCL and neuroblastoma has not been established. There is a need to develop new drugs for these patients. The objectives of this trial are to evaluate the tolerability and safety of crizotinib in Japanese patients with recurrent/refractory ALK-positive ALCL or neuroblastoma (phase I) and its efficacy in recurrent/refractory ALK-positive ALCL (phase II).

Original languageEnglish
Pages (from-to)431-436
Number of pages6
JournalActa medica Okayama
Volume72
Issue number4
Publication statusPublished - Jan 1 2018

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

Fingerprint Dive into the research topics of 'A Phase I/II study of crizotinib for recurrent or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma and a phase i study of crizotinib for recurrent or refractory neuroblastoma: Study protocol for a multicenter single-arm open-label trial'. Together they form a unique fingerprint.

  • Cite this